In a recent pilot study 50 AD patients were treated with lactoferrin for 3 months to find significant improvement in antioxidant and anti-inflammatory markers in serum, and decrease in Aβ42, phosphorylated tau, interleukin-6 and caspase-3 as well as improved cognitive function (Mohamed et al., 2019), possibly opening the doors toward new treatments in AD, however further follow-up data are required. Here, MAPT is linked to Alzheimer disease.